 <h1>Darunavir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of darunavir include:</b> skin rash. <b>Other side effects include:</b> nausea.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to darunavir: oral suspension, oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, darunavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking darunavir:</p><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>dry mouth</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>skin rash</li>
<li>sweating</li>
<li>trouble breathing</li>
<li>unexplained weight loss</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Belching</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>chills</li>
<li>constipation</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>excess air or gas in the stomach or bowels</li>
<li>fast heartbeat</li>
<li>feeling of fullness</li>
<li>fever</li>
<li>headache</li>
<li>heartburn</li>
<li>indigestion</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>lack or loss of strength</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>muscle aching or cramping</li>
<li>nausea</li>
<li>passing gas</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach pain or tenderness</li>
<li>swelling of the feet or lower legs</li>
<li>swollen joints</li>
<li>unpleasant breath odor</li>
<li>vomiting</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Muscle pain or stiffness</li>
<li>swelling or puffiness of the face</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of darunavir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Stuffy or runny nose</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Gaining weight around your neck, upper back, breast, face, or waist</li>
</ul><p>
<!-- end oral suspension, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to darunavir: oral suspension, oral tablet</i></p><h3>General</h3><p>The most common side effects reported with darunavir/cobicistat were diarrhea, nausea, and rash.  The manufacturer product information for cobicistat or cobicistat-darunavir should be consulted.</p>
<p></p>
<p>Most side effects reported during therapy with darunavir/ritonavir were mild in severity.  The most common side effects were diarrhea, nausea, vomiting, headache, rash, and abdominal pain.  Adverse events led to therapy discontinuation in 2.3% and 4.7% of therapy-naive and therapy-experienced subjects, respectively, in randomized trials.  The manufacturer product information for ritonavir should be consulted for ritonavir-associated side effects.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Darunavir/cobicistat:</p>
<p>-Very common (10% or more): Diarrhea (28%), nausea (23%)</p>
<p>-Common (1% to 10%): Vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, increased pancreatic enzymes</p>
<p>-Uncommon (0.1% to 1%): Acute pancreatitis</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Very common (10% or more): Diarrhea (up to 14.4%)</p>
<p>-Common (1% to 10%): Nausea, vomiting, abdominal pain, elevated pancreatic amylase, elevated pancreatic lipase, abdominal distension, dyspepsia, flatulence, elevated blood amylase</p>
<p>-Uncommon (0.1% to 1%): Pancreatitis, acute pancreatitis, gastritis, gastroesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, elevated lipase, eructation, oral dysesthesia</p>
<p>-Rare (less than 0.1%): Stomatitis, hematemesis, cheilitis, dry lip, coated tongue</p>
<p>-Frequency not reported: Elevated pancreatic enzyme<sup>[Ref]</sup></p><p>Elevated pancreatic amylase (grade 2: up to 7.4%; grade 3: up to 7.8%; grade 4: up to 1.1%) and pancreatic lipase (grade 2: 5.2%; grade 3: up to 2.6%; grade 4: less than 1%) have been reported with darunavir/ritonavir.<sup>[Ref]</sup></p><h3>Other</h3><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Fatigue</p>
<p>-Uncommon (0.1% to 1%): Asthenia</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Very common (10% or more): Elevated total cholesterol (up to 25%), elevated glucose levels (up to 15.4%), elevated low-density lipoprotein (LDL) cholesterol (up to 14.4%), elevated triglycerides (up to 10.4%)</p>
<p>-Common (1% to 10%): Asthenia, fatigue</p>
<p>-Uncommon (0.1% to 1%): Pyrexia, chest pain, peripheral edema, flushing, malaise, feeling hot, pain, decreased weight, increased weight, decreased high density lipoprotein, elevated blood alkaline phosphatase, elevated lactate dehydrogenase</p>
<p>-Rare (less than 0.1%): Chills, abnormal feeling, xerosis</p>
<p>-Frequency not reported: Rigors, hyperthermia, facial edema, decreased bicarbonate</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased weight, increased blood lipids<sup>[Ref]</sup></p><p>Elevated total cholesterol (grade 2: up to 25%; grade 3: up to 10%), LDL cholesterol (grade 2: 14.4%; grade 3: up to 9.1%), triglycerides (grade 2: up to 10.4%; grade 3: up to 8.2%; grade 4: up to 3.9%), and alkaline phosphatase (grade 2: up to 3.9%; grade 3: less than 1%) have been reported with darunavir/ritonavir.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In clinical trials, rashes were generally mild-to-moderate, often occurring within the first 4 weeks of therapy and resolving with continued use.<sup>[Ref]</sup></p><p>Darunavir/cobicistat:</p>
<p>-Very common (10% or more): Rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalized rash, allergic dermatitis; 16%)</p>
<p>-Common (1% to 10%): Angioedema, pruritus, urticaria</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Common (1% to 10%): Rash (including macular, maculopapular, papular, erythematous, pruritic rash), pruritus, lipodystrophy (including lipohypertrophy, lipodystrophy, lipoatrophy)</p>
<p>-Uncommon (0.1% to 1%): Angioedema, generalized rash, urticaria, night sweats, allergic dermatitis, eczema, erythema, alopecia, hyperhidrosis, Stevens-Johnson syndrome, acne, dry skin, nail pigmentation, herpes simplex, severe skin reactions (in some cases accompanied by fever and/or elevations of transaminases)</p>
<p>-Rare (less than 0.1%): Drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, dermatitis, seborrheic dermatitis, skin lesion, xeroderma</p>
<p>-Frequency not reported: Folliculitis, lipoatrophy, toxic skin eruption, dermatitis medicamentosa, skin inflammation</p>
<p>-Postmarketing reports: Toxic epidermal necrolysis, acute generalized exanthematous pustulosis, DRESS<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Elevated glucose levels (grade 2: up to 15.4%; grade 3: up to 1.7%; grade 4: less than 1%) has been reported with darunavir/ritonavir.<sup>[Ref]</sup></p><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Very common (10% or more): Elevated glucose levels (up to 15.4%)</p>
<p>-Common (1% to 10%): Hyperlipidemia, anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia</p>
<p>-Uncommon (0.1% to 1%): Gout, decreased appetite, polydipsia, hyperglycemia, insulin resistance, increased appetite</p>
<p>-Frequency not reported: Hypoglycemia, hyperuricemia, hypocalcemia, hyponatremia, hypernatremia, obesity, hypoalbuminemia</p>
<p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, ketoacidosis, redistribution of body fat</p>
<p></p>
<p>HIV protease inhibitors:</p>
<p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes, hyperglycemia, diabetic ketoacidosis</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased glucose, redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), metabolic abnormalities (such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia)<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Darunavir/cobicistat:</p>
<p>-Very common (10% or more): Headache</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Common (1% to 10%): Headache, peripheral neuropathy, dizziness</p>
<p>-Uncommon (0.1% to 1%): Lethargy, hypoesthesia, paresthesia, dysgeusia, disturbance in attention, memory impairment, somnolence, vertigo</p>
<p>-Rare (less than 0.1%): Syncope, convulsion, ageusia, sleep phase rhythm disturbance</p>
<p>-Frequency not reported: Transient ischemic attack, progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Increased hepatic enzyme</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Common (1% to 10%): Elevated ALT, elevated AST</p>
<p>-Uncommon (0.1% to 1%): Hepatitis, acute hepatitis, cytolytic hepatitis, hepatic steatosis, hepatotoxicity, elevated transaminase, elevated blood bilirubin/hyperbilirubinemia, elevated GGT</p>
<p>-Frequency not reported: Elevated hepatic enzymes</p>
<p>-Postmarketing reports: Liver injury (including fatalities)<sup>[Ref]</sup></p><p>Hyperbilirubinemia (grade 2: less than 1%; grade 3: less than 1%; grade 4: less than 1%), and elevated ALT (grade 2: up to 9%; grade 3: up to 3%; grade 4: up to 1%), and AST (grade 2: up to 7%; grade 3: up to 4.1%; grade 4: up to 1.2%) have been reported with darunavir/ritonavir.</p>
<p></p>
<p>In patients receiving darunavir/ritonavir, the incidence of side effects and clinical chemistry abnormalities was not higher in those coinfected with hepatitis B or C virus compared with patients who were not coinfected, with the exception of elevated hepatic enzymes.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Abnormal dreams</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Common (1% to 10%): Insomnia</p>
<p>-Uncommon (0.1% to 1%): Depression, disorientation, sleep disorder, abnormal dreams, nightmare, anxiety, decreased libido, irritability</p>
<p>-Rare (less than 0.1%): Confusion state, altered mood, restlessness<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Myocardial infarction, angina pectoris, prolonged ECG QT, tachycardia, hypertension</p>
<p>-Rare (less than 0.1%): Acute myocardial infarction, sinus bradycardia, palpitations<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Thrombocytopenia, neutropenia, anemia, leukopenia</p>
<p>-Rare (less than 0.1%): Elevated eosinophil count</p>
<p>-Frequency not reported: Decreased white blood cell count, decreased lymphocytes, decreased total absolute neutrophil count, decreased platelets, increased partial thromboplastin time, increased plasma prothrombin time</p>
<p></p>
<p>HIV protease inhibitors:</p>
<p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Renal</h3><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Increased blood creatinine</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Acute renal failure, renal failure, nephrolithiasis, elevated blood creatinine</p>
<p>-Rare (less than 0.1%): Decreased creatinine renal clearance</p>
<p>-Frequency not reported: Renal insufficiency<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Myalgia</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremities, osteoporosis, elevated blood creatine phosphokinase (CPK)</p>
<p>-Rare (less than 0.1%): Musculoskeletal stiffness, arthritis, joint stiffness</p>
<p>-Frequency not reported: Osteopenia</p>
<p>-Postmarketing reports: Rhabdomyolysis</p>
<p></p>
<p>HIV protease inhibitors:</p>
<p>-Frequency not reported: Increased CPK, myalgia, myositis, rhabdomyolysis<sup>[Ref]</sup></p><p>Osteonecrosis has been reported, particularly with commonly known risk factors (e.g., corticosteroid use, alcohol use, severe immunosuppression, higher body mass index), advanced HIV disease, or long-term combination antiretroviral therapy.</p>
<p></p>
<p>Increased CPK, myalgia, myositis, and rarely, rhabdomyolysis have been reported with HIV protease inhibitors, especially when coadministered with nucleoside reverse transcriptase inhibitors.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Dyspnea, cough, epistaxis, throat irritation</p>
<p>-Rare (less than 0.1%): Rhinorrhea</p>
<p>-Frequency not reported: Nasopharyngitis, hiccups, pneumonia, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Darunavir/cobicistat:</p>
<p>-Common (1% to 10%): Drug hypersensitivity</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria, erectile dysfunction</p>
<p>-Frequency not reported: Polyuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Darunavir/cobicistat:</p>
<p>-Uncommon (0.1% to 1%): Immune reconstitution inflammatory syndrome</p>
<p></p>
<p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Immune reconstitution inflammatory syndrome</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Hypothyroidism, elevated blood thyroid stimulating hormone, gynecomastia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Darunavir/ritonavir:</p>
<p>-Uncommon (0.1% to 1%): Conjunctival hyperemia, dry eye</p>
<p>-Rare (less than 0.1%): Visual disturbance<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Fenton C,  Perry CM "Darunavir: In the Treatment of HIV-1 Infection." Drugs 67 (2007): 2791-801</p><p id="ref_2">2. Rittweger M,  Arasteh K "Clinical pharmacokinetics of darunavir." Clin Pharmacokinet 46 (2007): 739-56</p><p id="ref_3">3. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_4">4. Taiwo BO,  Hicks CB "Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance." AIDS Read 17 (2007): 151-6, 159-61</p><p id="ref_5">5. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_6">6. Hoffman CJ,  Gallant JE "When and how to use tipranavir and darunavir." AIDS Read 17 (2007): 194-8, 201</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ. </p><p id="ref_9">9. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_10">10. McCoy C "Darunavir: a nonpeptidic antiretroviral protease inhibitor." Clin Ther 29 (2007): 1559-1576</p><p id="ref_11">11. Katlama C,  Esposito R,  Gatell JM, et al. "Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1." AIDS 21 (2007): 395-402</p><p id="ref_12">12. Sekar V,  Kestens D,  Spinosa-Guzman S, et al. "The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers." J Clin Pharmacol 47 (2007): 479-84</p><p id="ref_13">13. Clotet B,  Bellos N,  Molina JM, et al. "Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials." Lancet 369 (2007): 1169-78</p><p id="ref_14">14. "Darunavir (Prezista) for HIV infection." Med Lett Drugs Ther 48 (2006): 74-5</p><p id="ref_15">15. Busse KH,  Penzak SR "Darunavir: A second-generation protease inhibitor." Am J Health Syst Pharm 64 (2007): 1593-602</p><p id="ref_16">16. Holodniy M "Darunavir in the Treatment of HIV-1 Infection: A Viewpoint by Mark Holodniy." Drugs 67 (2007): 2802-3</p><p id="ref_17">17. Poveda E,  Blanco F,  Garcia-Gasco P,  Alcolea A,  Briz V,  Soriano V "Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors." AIDS 20 (2006): 1558-60</p><p id="ref_18">18. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What drugs are contained in the HIV treatment Symtuza?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about darunavir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (4)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Darunavir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Prezista</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to darunavir: oral suspension, oral tablet</i></p><h3>General</h3><p>The most common side effects reported with darunavir/cobicistat were diarrhea, nausea, and rash.  The manufacturer product information for cobicistat or cobicistat-darunavir should be consulted.</p><p></p><p>Most side effects reported during therapy with darunavir/ritonavir were mild in severity.  The most common side effects were diarrhea, nausea, vomiting, headache, rash, and abdominal pain.  Adverse events led to therapy discontinuation in 2.3% and 4.7% of therapy-naive and therapy-experienced subjects, respectively, in randomized trials.  The manufacturer product information for ritonavir should be consulted for ritonavir-associated side effects.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Darunavir/cobicistat:</p><p>-Very common (10% or more): Diarrhea (28%), nausea (23%)</p><p>-Common (1% to 10%): Vomiting, abdominal pain, abdominal distension, dyspepsia, flatulence, increased pancreatic enzymes</p><p>-Uncommon (0.1% to 1%): Acute pancreatitis</p><p></p><p>Darunavir/ritonavir:</p><p>-Very common (10% or more): Diarrhea (up to 14.4%)</p><p>-Common (1% to 10%): Nausea, vomiting, abdominal pain, elevated pancreatic amylase, elevated pancreatic lipase, abdominal distension, dyspepsia, flatulence, elevated blood amylase</p><p>-Uncommon (0.1% to 1%): Pancreatitis, acute pancreatitis, gastritis, gastroesophageal reflux disease, aphthous stomatitis, retching, dry mouth, abdominal discomfort, constipation, elevated lipase, eructation, oral dysesthesia</p><p>-Rare (less than 0.1%): Stomatitis, hematemesis, cheilitis, dry lip, coated tongue</p><p>-Frequency not reported: Elevated pancreatic enzyme<sup>[Ref]</sup></p><p>Elevated pancreatic amylase (grade 2: up to 7.4%; grade 3: up to 7.8%; grade 4: up to 1.1%) and pancreatic lipase (grade 2: 5.2%; grade 3: up to 2.6%; grade 4: less than 1%) have been reported with darunavir/ritonavir.<sup>[Ref]</sup></p><h3>Other</h3><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Fatigue</p><p>-Uncommon (0.1% to 1%): Asthenia</p><p></p><p>Darunavir/ritonavir:</p><p>-Very common (10% or more): Elevated total cholesterol (up to 25%), elevated glucose levels (up to 15.4%), elevated low-density lipoprotein (LDL) cholesterol (up to 14.4%), elevated triglycerides (up to 10.4%)</p><p>-Common (1% to 10%): Asthenia, fatigue</p><p>-Uncommon (0.1% to 1%): Pyrexia, chest pain, peripheral edema, flushing, malaise, feeling hot, pain, decreased weight, increased weight, decreased high density lipoprotein, elevated blood alkaline phosphatase, elevated lactate dehydrogenase</p><p>-Rare (less than 0.1%): Chills, abnormal feeling, xerosis</p><p>-Frequency not reported: Rigors, hyperthermia, facial edema, decreased bicarbonate</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased weight, increased blood lipids<sup>[Ref]</sup></p><p>Elevated total cholesterol (grade 2: up to 25%; grade 3: up to 10%), LDL cholesterol (grade 2: 14.4%; grade 3: up to 9.1%), triglycerides (grade 2: up to 10.4%; grade 3: up to 8.2%; grade 4: up to 3.9%), and alkaline phosphatase (grade 2: up to 3.9%; grade 3: less than 1%) have been reported with darunavir/ritonavir.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>In clinical trials, rashes were generally mild-to-moderate, often occurring within the first 4 weeks of therapy and resolving with continued use.<sup>[Ref]</sup></p><p>Darunavir/cobicistat:</p><p>-Very common (10% or more): Rash (including macular, maculopapular, papular, erythematous, pruritic rash, generalized rash, allergic dermatitis; 16%)</p><p>-Common (1% to 10%): Angioedema, pruritus, urticaria</p><p></p><p>Darunavir/ritonavir:</p><p>-Common (1% to 10%): Rash (including macular, maculopapular, papular, erythematous, pruritic rash), pruritus, lipodystrophy (including lipohypertrophy, lipodystrophy, lipoatrophy)</p><p>-Uncommon (0.1% to 1%): Angioedema, generalized rash, urticaria, night sweats, allergic dermatitis, eczema, erythema, alopecia, hyperhidrosis, Stevens-Johnson syndrome, acne, dry skin, nail pigmentation, herpes simplex, severe skin reactions (in some cases accompanied by fever and/or elevations of transaminases)</p><p>-Rare (less than 0.1%): Drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, dermatitis, seborrheic dermatitis, skin lesion, xeroderma</p><p>-Frequency not reported: Folliculitis, lipoatrophy, toxic skin eruption, dermatitis medicamentosa, skin inflammation</p><p>-Postmarketing reports: Toxic epidermal necrolysis, acute generalized exanthematous pustulosis, DRESS<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Elevated glucose levels (grade 2: up to 15.4%; grade 3: up to 1.7%; grade 4: less than 1%) has been reported with darunavir/ritonavir.<sup>[Ref]</sup></p><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia</p><p></p><p>Darunavir/ritonavir:</p><p>-Very common (10% or more): Elevated glucose levels (up to 15.4%)</p><p>-Common (1% to 10%): Hyperlipidemia, anorexia, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia</p><p>-Uncommon (0.1% to 1%): Gout, decreased appetite, polydipsia, hyperglycemia, insulin resistance, increased appetite</p><p>-Frequency not reported: Hypoglycemia, hyperuricemia, hypocalcemia, hyponatremia, hypernatremia, obesity, hypoalbuminemia</p><p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia, ketoacidosis, redistribution of body fat</p><p></p><p>HIV protease inhibitors:</p><p>-Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes, hyperglycemia, diabetic ketoacidosis</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased glucose, redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), metabolic abnormalities (such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, hyperlactatemia)<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Darunavir/cobicistat:</p><p>-Very common (10% or more): Headache</p><p></p><p>Darunavir/ritonavir:</p><p>-Common (1% to 10%): Headache, peripheral neuropathy, dizziness</p><p>-Uncommon (0.1% to 1%): Lethargy, hypoesthesia, paresthesia, dysgeusia, disturbance in attention, memory impairment, somnolence, vertigo</p><p>-Rare (less than 0.1%): Syncope, convulsion, ageusia, sleep phase rhythm disturbance</p><p>-Frequency not reported: Transient ischemic attack, progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Increased hepatic enzyme</p><p></p><p>Darunavir/ritonavir:</p><p>-Common (1% to 10%): Elevated ALT, elevated AST</p><p>-Uncommon (0.1% to 1%): Hepatitis, acute hepatitis, cytolytic hepatitis, hepatic steatosis, hepatotoxicity, elevated transaminase, elevated blood bilirubin/hyperbilirubinemia, elevated GGT</p><p>-Frequency not reported: Elevated hepatic enzymes</p><p>-Postmarketing reports: Liver injury (including fatalities)<sup>[Ref]</sup></p><p>Hyperbilirubinemia (grade 2: less than 1%; grade 3: less than 1%; grade 4: less than 1%), and elevated ALT (grade 2: up to 9%; grade 3: up to 3%; grade 4: up to 1%), and AST (grade 2: up to 7%; grade 3: up to 4.1%; grade 4: up to 1.2%) have been reported with darunavir/ritonavir.</p><p></p><p>In patients receiving darunavir/ritonavir, the incidence of side effects and clinical chemistry abnormalities was not higher in those coinfected with hepatitis B or C virus compared with patients who were not coinfected, with the exception of elevated hepatic enzymes.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Abnormal dreams</p><p></p><p>Darunavir/ritonavir:</p><p>-Common (1% to 10%): Insomnia</p><p>-Uncommon (0.1% to 1%): Depression, disorientation, sleep disorder, abnormal dreams, nightmare, anxiety, decreased libido, irritability</p><p>-Rare (less than 0.1%): Confusion state, altered mood, restlessness<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Myocardial infarction, angina pectoris, prolonged ECG QT, tachycardia, hypertension</p><p>-Rare (less than 0.1%): Acute myocardial infarction, sinus bradycardia, palpitations<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Thrombocytopenia, neutropenia, anemia, leukopenia</p><p>-Rare (less than 0.1%): Elevated eosinophil count</p><p>-Frequency not reported: Decreased white blood cell count, decreased lymphocytes, decreased total absolute neutrophil count, decreased platelets, increased partial thromboplastin time, increased plasma prothrombin time</p><p></p><p>HIV protease inhibitors:</p><p>-Frequency not reported: Increased bleeding (including spontaneous skin hematomas, hemarthrosis) in hemophiliacs<sup>[Ref]</sup></p><h3>Renal</h3><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Increased blood creatinine</p><p></p><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Acute renal failure, renal failure, nephrolithiasis, elevated blood creatinine</p><p>-Rare (less than 0.1%): Decreased creatinine renal clearance</p><p>-Frequency not reported: Renal insufficiency<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Myalgia</p><p></p><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Myalgia, osteonecrosis, muscle spasms, muscular weakness, arthralgia, pain in extremities, osteoporosis, elevated blood creatine phosphokinase (CPK)</p><p>-Rare (less than 0.1%): Musculoskeletal stiffness, arthritis, joint stiffness</p><p>-Frequency not reported: Osteopenia</p><p>-Postmarketing reports: Rhabdomyolysis</p><p></p><p>HIV protease inhibitors:</p><p>-Frequency not reported: Increased CPK, myalgia, myositis, rhabdomyolysis<sup>[Ref]</sup></p><p>Osteonecrosis has been reported, particularly with commonly known risk factors (e.g., corticosteroid use, alcohol use, severe immunosuppression, higher body mass index), advanced HIV disease, or long-term combination antiretroviral therapy.</p><p></p><p>Increased CPK, myalgia, myositis, and rarely, rhabdomyolysis have been reported with HIV protease inhibitors, especially when coadministered with nucleoside reverse transcriptase inhibitors.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Dyspnea, cough, epistaxis, throat irritation</p><p>-Rare (less than 0.1%): Rhinorrhea</p><p>-Frequency not reported: Nasopharyngitis, hiccups, pneumonia, upper respiratory tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Darunavir/cobicistat:</p><p>-Common (1% to 10%): Drug hypersensitivity</p><p></p><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Proteinuria, bilirubinuria, dysuria, nocturia, pollakiuria, erectile dysfunction</p><p>-Frequency not reported: Polyuria<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Darunavir/cobicistat:</p><p>-Uncommon (0.1% to 1%): Immune reconstitution inflammatory syndrome</p><p></p><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Immune reconstitution inflammatory syndrome</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Hypothyroidism, elevated blood thyroid stimulating hormone, gynecomastia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Darunavir/ritonavir:</p><p>-Uncommon (0.1% to 1%): Conjunctival hyperemia, dry eye</p><p>-Rare (less than 0.1%): Visual disturbance<sup>[Ref]</sup></p><p id="ref_1">1. Fenton C,  Perry CM "Darunavir: In the Treatment of HIV-1 Infection." Drugs 67 (2007): 2791-801</p><p id="ref_2">2. Rittweger M,  Arasteh K "Clinical pharmacokinetics of darunavir." Clin Pharmacokinet 46 (2007): 739-56</p><p id="ref_3">3. "Drugs for HIV infection." Treat Guidel Med Lett 7 (2009): 11-22</p><p id="ref_4">4. Taiwo BO,  Hicks CB "Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance." AIDS Read 17 (2007): 151-6, 159-61</p><p id="ref_5">5. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_6">6. Hoffman CJ,  Gallant JE "When and how to use tipranavir and darunavir." AIDS Read 17 (2007): 194-8, 201</p><p id="ref_7">7. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_8">8. "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ. </p><p id="ref_9">9. Warnke D,  Barreto J,  Temesgen Z "Antiretroviral drugs." J Clin Pharmacol 47 (2007): 1570-9</p><p id="ref_10">10. McCoy C "Darunavir: a nonpeptidic antiretroviral protease inhibitor." Clin Ther 29 (2007): 1559-1576</p><p id="ref_11">11. Katlama C,  Esposito R,  Gatell JM, et al. "Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1." AIDS 21 (2007): 395-402</p><p id="ref_12">12. Sekar V,  Kestens D,  Spinosa-Guzman S, et al. "The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers." J Clin Pharmacol 47 (2007): 479-84</p><p id="ref_13">13. Clotet B,  Bellos N,  Molina JM, et al. "Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials." Lancet 369 (2007): 1169-78</p><p id="ref_14">14. "Darunavir (Prezista) for HIV infection." Med Lett Drugs Ther 48 (2006): 74-5</p><p id="ref_15">15. Busse KH,  Penzak SR "Darunavir: A second-generation protease inhibitor." Am J Health Syst Pharm 64 (2007): 1593-602</p><p id="ref_16">16. Holodniy M "Darunavir in the Treatment of HIV-1 Infection: A Viewpoint by Mark Holodniy." Drugs 67 (2007): 2802-3</p><p id="ref_17">17. Poveda E,  Blanco F,  Garcia-Gasco P,  Alcolea A,  Briz V,  Soriano V "Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors." AIDS 20 (2006): 1558-60</p><p id="ref_18">18. Borras-Blasco J,  Navarro-Ruiz A,  Borras C,  Castera E "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother 62 (2008): 879-88</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What drugs are contained in the HIV treatment Symtuza?</li>
</ul><h2>More about darunavir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: protease inhibitors</li>
<li>FDA Alerts (4)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Darunavir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>